CDKN1B and cancer: More recently, Mirk/Dyrk1B has been found to contribute G0 arrest and maintain viability of the quiescent cancer cells via mediating cyclin D1 and p27kip1 which is associated with reduction of reactive oxygen species (ROS) [5,13], therefore, we hypothesize that Mirk/Dyrk1B pathway may be a novel target for overcoming the drug-resistance and recurrence of various human cancers.